| Primary |
| Stem Cell Transplant |
59.8% |
| Bone Marrow Conditioning Regimen |
12.7% |
| Product Used For Unknown Indication |
6.3% |
| Prophylaxis Against Graft Versus Host Disease |
3.0% |
| Bone Marrow Transplant |
2.9% |
| Acute Myeloid Leukaemia |
2.7% |
| Cord Blood Transplant Therapy |
2.2% |
| Allogenic Bone Marrow Transplantation Therapy |
2.0% |
| Chemotherapy |
1.7% |
| Myeloid Leukaemia |
1.1% |
| B-cell Lymphoma |
0.8% |
| Haematological Malignancy |
0.8% |
| Transplant |
0.8% |
| Plasma Cell Myeloma |
0.6% |
| Chronic Myeloid Leukaemia |
0.5% |
| Graft Versus Host Disease |
0.4% |
| Infection Prophylaxis |
0.4% |
| Lymphoma |
0.4% |
| Prophylaxis |
0.4% |
| Antifungal Prophylaxis |
0.4% |
|
| Vomiting |
14.7% |
| Stomatitis |
12.8% |
| Venoocclusive Liver Disease |
12.6% |
| Thrombotic Microangiopathy |
6.0% |
| Venoocclusive Disease |
5.1% |
| Sepsis |
4.9% |
| Stem Cell Transplant |
4.6% |
| Acute Graft Versus Host Disease |
3.9% |
| Leukaemia Recurrent |
3.8% |
| Transplant Failure |
3.5% |
| Death |
3.3% |
| Graft Versus Host Disease |
3.2% |
| Chronic Graft Versus Host Disease |
3.0% |
| Cytomegalovirus Infection |
3.0% |
| Infection |
3.0% |
| White Blood Cell Count Decreased |
2.8% |
| Mucosal Inflammation |
2.7% |
| Weight Increased |
2.5% |
| Recurrent Cancer |
2.4% |
| Malignant Neoplasm Progression |
2.2% |
|
| Secondary |
| Prophylaxis Against Graft Versus Host Disease |
18.7% |
| Bone Marrow Conditioning Regimen |
12.4% |
| Stem Cell Transplant |
11.1% |
| Infection Prophylaxis |
9.6% |
| Prophylaxis |
7.2% |
| Acute Myeloid Leukaemia |
4.1% |
| Product Used For Unknown Indication |
4.1% |
| Antibiotic Prophylaxis |
3.9% |
| Chronic Myeloid Leukaemia |
3.9% |
| Myelodysplastic Syndrome |
3.7% |
| Bone Marrow Transplant |
3.5% |
| Graft Versus Host Disease |
2.6% |
| Multiple Myeloma |
2.6% |
| Cord Blood Transplant Therapy |
2.2% |
| Convulsion Prophylaxis |
2.0% |
| Drug Use For Unknown Indication |
2.0% |
| Haematological Malignancy |
2.0% |
| Leukaemia |
2.0% |
| Abdominal Pain |
1.3% |
| Allogenic Bone Marrow Transplantation Therapy |
1.3% |
|
| Thrombotic Microangiopathy |
16.2% |
| Venoocclusive Liver Disease |
12.2% |
| Vomiting |
8.1% |
| Aplastic Anaemia |
5.4% |
| Hepatotoxicity |
5.4% |
| Mucosal Inflammation |
5.4% |
| Neutropenia |
5.4% |
| Venoocclusive Disease |
5.4% |
| Cerebral Haemorrhage |
4.1% |
| Nausea |
4.1% |
| Respiratory Failure |
4.1% |
| Weight Increased |
4.1% |
| Death |
2.7% |
| Infection |
2.7% |
| Pneumonia |
2.7% |
| Pneumonitis |
2.7% |
| Rash |
2.7% |
| Renal Failure Acute |
2.7% |
| Squamous Cell Carcinoma |
2.7% |
| Acute Myeloid Leukaemia |
1.4% |
|
| Concomitant |
| Drug Use For Unknown Indication |
17.3% |
| Acute Myeloid Leukaemia |
10.5% |
| Prophylaxis Against Graft Versus Host Disease |
9.5% |
| Product Used For Unknown Indication |
8.2% |
| Acute Lymphocytic Leukaemia |
6.1% |
| Convulsion Prophylaxis |
5.5% |
| Packed Red Blood Cell Transfusion |
5.1% |
| Platelet Transfusion |
5.1% |
| Prophylaxis |
4.8% |
| Bone Marrow Conditioning Regimen |
3.9% |
| Infection Prophylaxis |
3.7% |
| Cord Blood Transplant Therapy |
3.0% |
| Allogenic Bone Marrow Transplantation Therapy |
2.7% |
| Stem Cell Transplant |
2.5% |
| Surgical Preconditioning |
2.3% |
| Myelodysplastic Syndrome |
2.2% |
| Blood Product Transfusion |
2.1% |
| Follicle Centre Lymphoma, Follicular Grade I, Ii, Iii |
2.1% |
| Haematopoietic Stem Cell Mobilisation |
1.9% |
| Bone Marrow Transplant |
1.5% |
|
| Sepsis |
21.6% |
| Thrombotic Microangiopathy |
16.5% |
| Renal Failure Acute |
6.2% |
| Thrombocytopenia |
6.2% |
| White Blood Cell Count Decreased |
6.2% |
| Cytomegalovirus Viraemia |
4.1% |
| Pyrexia |
4.1% |
| Systemic Candida |
4.1% |
| Venoocclusive Disease |
4.1% |
| Pneumonia Respiratory Syncytial Viral |
3.1% |
| Venoocclusive Liver Disease |
3.1% |
| Viral Haemorrhagic Cystitis |
3.1% |
| Vomiting |
3.1% |
| Acute Graft Versus Host Disease |
2.1% |
| Acute Myeloid Leukaemia |
2.1% |
| Death |
2.1% |
| Encephalitis Herpes |
2.1% |
| Febrile Neutropenia |
2.1% |
| Graft Versus Host Disease |
2.1% |
| Infection |
2.1% |
|
